IRLAB announces the outcome of the company’s rights issue
IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) announces today, 18 July 2025 the outcome of the rights issue of shares of series A up to approximately SEK 136 million, which the Board of Directors resolved on 24 June 2025 by virtue of the authorization from the Annual General Meeting (the “Rights Issue”). The Company has received the outcome of the Rights Issue which concludes that 18,931,197 shares, corresponding to approximately 48.7 percent of the Rights Issue, have been subscribed for with the support of subscription rights. Additionally, applications for subscription of 4,838,083 shares, corresponding to approximately 12.4 percent of the Rights Issue, have been received for subscription of shares without the support of subscription rights. In aggregate, the subscriptions with the support of subscription rights and the applications for subscription without the support of subscription rights correspond to approximately 61.1 percent of the Rights Issue. Hence, guarantee undertakings of 9,300,334 shares, corresponding to approximately 23.9 percent of the Rights Issue, will be utilized. The Rights Issue will provide the Company with proceeds of approximately SEK 115.7 million before deduction of costs related to the Rights Issue and set-off of loans. The Company’s Board of Directors has resolved, in connection with the allocation, to allow the set-off of outstanding loans.
Read More >IRLAB carries out SEK 136m rights issue
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >